PGY-2, Department of Podiatric Medicine and Surgery, Scripps Mercy Hospital, San Diego, CA 92103, United States.
Podiatric Surgery Section Chief, Scripps Mercy Hospital, 4077 Fifth Ave, MER35, San Diego, CA, 92103, United States.
Curr Pharm Biotechnol. 2020;21(5):390-402. doi: 10.2174/1389201020666191202111534.
Peripheral neuropathy can significantly impact the quality of life for those who are affected, as therapies from the current treatment algorithm often fail to deliver adequate symptom relief. There has, however, been an increasing body of evidence for the use of cannabinoids in the treatment of chronic, noncancer pain. The efficacy of a topically delivered cannabidiol (CBD) oil in the management of neuropathic pain was examined in this four-week, randomized and placebocontrolled trial.
In total, 29 patients with symptomatic peripheral neuropathy were recruited and enrolled. 15 patients were randomized to the CBD group with the treatment product containing 250 mg CBD/3 fl. oz, and 14 patients were randomized to the placebo group. After four weeks, the placebo group was allowed to crossover into the treatment group. The Neuropathic Pain Scale (NPS) was administered biweekly to assess the mean change from baseline to the end of the treatment period.
The study population included 62.1% males and 37.9% females with a mean age of 68 years. There was a statistically significant reduction in intense pain, sharp pain, cold and itchy sensations in the CBD group when compared to the placebo group. No adverse events were reported in this study.
Our findings demonstrate that the transdermal application of CBD oil can achieve significant improvement in pain and other disturbing sensations in patients with peripheral neuropathy. The treatment product was well tolerated and may provide a more effective alternative compared to other current therapies in the treatment of peripheral neuropathy.
周围神经病变会显著影响患者的生活质量，因为当前治疗方案中的疗法常常无法充分缓解症状。然而，越来越多的证据表明大麻素可用于治疗慢性非癌性疼痛。本四周、随机、安慰剂对照试验旨在研究局部给予大麻二酚 (CBD) 油治疗神经性疼痛的疗效。
共招募并纳入了 29 名有症状的周围神经病患者。15 名患者随机分配至 CBD 组，给予含 250 mg CBD/3 液量的治疗产品，14 名患者随机分配至安慰剂组。四周后，安慰剂组允许交叉进入治疗组。使用神经性疼痛量表 (NPS) 每两周评估一次，评估从基线到治疗期末的平均变化。
研究人群包括 62.1%的男性和 37.9%的女性，平均年龄为 68 岁。与安慰剂组相比，CBD 组的剧烈疼痛、刺痛、冷感和瘙痒感有统计学显著降低。本研究未报告不良事件。
我们的研究结果表明，局部给予 CBD 油可显著改善周围神经病患者的疼痛和其他不适感觉。该治疗产品耐受性良好，与其他当前治疗周围神经病的疗法相比，可能是一种更有效的替代疗法。
